Give Online: Help shape patient care for generations to come.
Cleveland Clinic Logo

Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
3952  Collection of Blood and Bone Marrow from Allogeneic Hematopoietic Cell Transplant Recipients and their Related Donors Main Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
AGSP 1Z15 15-519 A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation Main Campus Phase 1Leukemia, Acute Myeloid (AML)
AROG 1915 15-742 A Safety and Tolerability Trial of Crenolanib and Chemotherapy with Cytarabine and Anthracyclines in Patients with Newly Diagnosed Acute Myeloid Leukemia with FLT3 Activating Mutations Main Campus  Leukemia, Acute Myeloid (AML)
CASE 2914 15-851 A Randomized Phase II Trial to Simultaneously Evaluate Two Schedules of the Histone Deacetylase Inhibitor Entinostat in Combination with 5-Azacytidine (5AC, NSC 102816) in Elderly Patients with Acute Myeloid Leukemia (AML) Main Campus Phase 2Leukemia, Acute Myeloid (AML)
CASE 491314-147 A Single Arm, Phase II study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients with Acute Myeloid Leukemia undergoing Remission Induction therapy Main Campus Phase 2Leukemia, Acute Myeloid (AML)
CASE 791314-492 A Phase 1 Study of MLN9708 in Combination with MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) Main Campus Phase 1Leukemia, Acute Myeloid (AML)
CLGN 1915 16-222 A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects with Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation. Main Campus Phase 3Leukemia, Acute Myeloid (AML)
FHCRC 191314-207 Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study Main Campus Phase 4Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
GMI 1915 15-933 A Phase I/II, open-label multicenter study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia Main Campus Phase 1, Phase 2Leukemia, Acute Myeloid (AML)
MLNM 1915 16-190 A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia Main Campus Phase 2Leukemia, Acute Myeloid (AML), Leukemia, Chronic Myelomonocytic (CMML), Myelodysplastic Syndrome (MDS)
SEGE 191313-1393 A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia Main Campus Phase 1Leukemia, Acute Myeloid (AML)
SEGE 1914 15-144 A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML) Main Campus Phase 1Leukemia, Acute Myeloid (AML)
SWOG 0919CC777 A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia Main Campus Phase 2Leukemia, Acute Myeloid (AML)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.